Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI-Reference-Cited by-同舟云学术

Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI

Published:2017-11-09 Issue:11 Volume:12 Page:e0187824
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chen Yi-Fang^ORCID,Yuan Ang,Cho Kuan-Hung,Lu Yi-Chien,Kuo Mark Yen-Ping,Chen Jyh-Horng,Chang Yeun-Chung

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcome;CG Slatore;Am J Respir Crit Care Med,2010

2. What is the evidence that tumors are angiogenesis dependent?;J Folkman;J Natl Cancer Inst,1990

3. Clinical applications of research on angiogenesis;J Folkman;N Engl J Med,1995

4. Intratumoral microvessel density as a prognostic factor in cancer;N Weidner;Am J Pathol,1995

5. Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer;A Sandler;N Engl J Med,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways;Molecules;2022-05-30

2. Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancer;PLOS ONE;2022-03-08

3. Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer;Integrative Cancer Therapies;2022-01

4. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors;Cancer Immunology, Immunotherapy;2020-08-06

5. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab;Biomedicine & Pharmacotherapy;2020-05